# Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

> **NCT06231381** · PHASE2 · RECRUITING · sponsor: **Shanghai Huaota Biopharmaceutical Co., Ltd.** · enrollment: 33 (estimated)

## Conditions studied

- Generalized Pustular Psoriasis (GPP)

## Interventions

- **DRUG:** HB0034
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06231381
- **Lead sponsor:** Shanghai Huaota Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-11-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06231381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06231381, "Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06231381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*